Kidney Support, Blood Sugar, and Adrenal Health

Evidence Review

Zhang, Li & Jia 2008 — Comprehensive Pharmacological Review

This landmark review in the Journal of Ethnopharmacology [1] remains the most cited English-language synthesis of Rehmannia's chemistry and pharmacology. The authors analyzed more than 70 identified compounds and mapped their biological activities across organ systems.

Key pharmacological actions documented:

Blood system: Rehmannia polysaccharides promote hematopoiesis — the production of blood cells — and protect bone marrow from suppression. This is consistent with its traditional use for blood deficiency syndromes.

Immune system: Both stimulatory and modulatory effects were documented, including activation of macrophages, enhancement of T-cell and NK-cell activity, and anti-inflammatory cytokine modulation. The net effect is immunomodulatory rather than simply immunostimulatory.

Endocrine system: Catalpol and other constituents influence insulin secretion, adrenocortical function, and thyroid hormone metabolism. The review confirmed HPA axis modulation, specifically antagonism of glucocorticoid-induced suppression.

Cardiovascular system: Cardioprotective effects include hypotensive activity (reduction of blood pressure), reduced lipid peroxidation, and protection against atherosclerosis in animal models.

Nervous system: Catalpol has neuroprotective properties — in models of neurodegeneration, it reduced neuronal death and preserved acetylcholine neurotransmitter levels, suggesting potential relevance in cognitive aging.

The authors noted that despite the breadth of preclinical evidence, rigorous large-scale clinical trials were limited at the time of publication, and called for more work to establish dose-response relationships and pharmacokinetic profiles in humans.

Qiu et al. 2014 — Randomized Controlled Trial in Chronic Glomerulonephritis

Published in Phytotherapy Research [2], this trial is the strongest human evidence for Rehmannia's kidney-protective effects. The study enrolled 479 patients diagnosed with primary chronic glomerulonephritis (CGN) — a common cause of progressive kidney disease — and randomized them to:

• Treatment group: Rehmannia glutinosa acteosides 400 mg/day + irbesartan 150 mg/day
• Control group: irbesartan 150 mg/day alone

Duration: 8 weeks. Primary endpoint: 24-hour urinary protein.

Results:

• Treatment group: 36.42% reduction in 24-h proteinuria from baseline (p < 0.001 vs baseline)
• Control group: 27.97% reduction (p < 0.001 vs baseline)
• Between-group difference: p = 0.0278, statistically significant
• No significant between-group differences in adverse events, liver enzymes, electrolytes, or blood pressure

The 36 vs 28% difference in proteinuria reduction represents a clinically meaningful additive benefit. Urinary protein is a direct marker of glomerular damage and a predictor of disease progression to end-stage renal failure. The study's large sample size (479 patients) and randomized design make this one of the better-quality trials available for a traditional Chinese herb in a specific clinical population.

Limitations include the relatively short 8-week duration, the use of combination therapy rather than Rehmannia alone, and the absence of long-term follow-up on hard outcomes like doubling of serum creatinine or dialysis initiation.

Zhou et al. 2015 — Rehmannia Polysaccharide in Diabetic Models

Published in the Journal of Ethnopharmacology [3], this study examined purified Rehmannia glutinosa polysaccharide (RGP) in streptozotocin (STZ)-induced diabetic mice — a well-established model of type 1-like diabetes.

The design compared diabetic untreated mice, diabetic mice receiving RGP (50, 100, or 200 mg/kg/day), and healthy controls over 4 weeks of oral treatment.

Key outcomes at the 200 mg/kg dose:

• Blood glucose: significantly reduced vs untreated diabetic mice; approached but did not reach normal control levels
• Total cholesterol: significantly reduced (dyslipidemia is a major complication of diabetes)
• Triglycerides: significantly reduced
• TNF-α and IL-6 (vascular inflammation markers): significantly reduced, suggesting attenuation of the chronic low-grade inflammation driving diabetic vascular disease
• Superoxide dismutase (SOD) activity: significantly increased, indicating improved antioxidant defense
• Malondialdehyde: significantly reduced, indicating less oxidative damage to lipids

Insulin levels in the RGP group were significantly higher than the untreated diabetic group, suggesting partial preservation or restoration of beta-cell function.

The researchers proposed that RGP acts through multiple mechanisms: direct antioxidant activity protecting islet cells, anti-inflammatory cytokine suppression reducing islet inflammation, and possible enhancement of insulin signaling in peripheral tissues.

Limitations: this is an animal study using an induction model of diabetes rather than type 2 diabetes, and the dose required to demonstrate effects in mice does not translate directly to human doses. Human clinical trials specifically testing Rehmannia polysaccharide for blood sugar management have not yet been published.

Kim, Yook & Kim 2017 — Review of Korean Clinical Publications

Published in the Journal of Pharmacopuncture [4], this review systematically examined 30 Korean-language publications on Rehmanniae Radix published through 2017 — a body of literature largely unavailable to English-language researchers.

The review categorized findings across:

• Antioxidant effects (12 publications): consistently demonstrated, across multiple extraction methods and tissue types
• Blood glucose reduction (4 publications): confirmed across both in vitro and clinical settings, consistent with the polysaccharide research
• Autonomic nervous system effects (3 publications): several studies showed that Rehmannia pharmacopuncture at specific acupoints affected heart rate variability, suggesting influence on autonomic tone
• Human clinical effects (11 publications): covering applications in hypertension, diabetes, and inflammatory conditions

The review concluded that Rehmanniae Radix is "effective in treating patients with various inflammatory and metabolic diseases, such as high blood pressure and diabetes," while acknowledging the need for larger-scale randomized controlled trials in Western clinical populations.

Srivastava, Huang & Jagtap 2024 — Randomized Skin Health Trial

Published in Clinical, Cosmetic and Investigational Dermatology [5], this double-blind, placebo-controlled proof-of-concept trial enrolled 22 women aged 18–35 with moderate-to-severe acne vulgaris (Global Acne Grading System scores 19–38) and randomized them to Rehmannia glutinosa leaf extract (RGLE) 100 mg/day or placebo for 56 days.

Results:

• GAGS score reduction: 21.7% in the RGLE group vs 14.2% in placebo by day 28; effect maintained at day 56
• Skin hydration: improved significantly in the RGLE group vs placebo
• Quality of life (DLQI): improvement trend favoring RGLE
• No adverse events in either group

This is a small pilot trial (n=22), and the lack of statistical significance reporting for between-group differences limits conclusions. However, the proof-of-concept finding that oral Rehmannia leaf extract reduces acne severity and improves skin hydration adds a skin health dimension to the herb's profile and provides a basis for larger confirmatory studies.

The active compounds in the leaf extract (primarily verbascoside and related phenylethanoid glycosides) have known anti-inflammatory and antioxidant activities relevant to acne pathogenesis, providing a mechanistic rationale consistent with the observed findings.

Evidence Strength Summary

Kidney protection: Moderate to high — one high-quality RCT (n=479) showing significant additive benefit on proteinuria, supported by consistent mechanistic evidence. Confidence: moderate-to-high.

Blood sugar regulation: Moderate — strong and consistent animal evidence with mechanistic clarity; human clinical trials specifically for this indication are lacking. Confidence: moderate.

Adrenal/HPA support: Low to moderate — preclinical evidence is coherent and mechanistically plausible; no randomized human trials for this specific application. Confidence: low-to-moderate.

Anti-inflammatory effects: Moderate — consistently demonstrated across multiple models and preparation types; catalpol's NF-κB inhibition is well characterized. Confidence: moderate.

Skin health: Low to moderate — one small pilot RCT with encouraging results; requires larger confirmatory trials. Confidence: low-to-moderate.

Overall, Rehmannia's strongest clinical evidence is in kidney disease, where an RCT demonstrates meaningful benefit. Its metabolic and anti-inflammatory applications are supported by preclinical data with good mechanistic coherence but await rigorous human trials for confirmation.